Skip to main content
News Icon

News categories: Publication

Heinsberg-Study Published

Bonn-based research team determine COVID-19 infection fatality ratein "Heinsberg Study"

The district of Heinsberg in the German state of North Rhine-Westphalia is considered a hot spot for the novel Coronavirus SARS-CoV-2. Following a carnival celebration, the district became one of the first areas in Germany where the pathogen spread and infected large quantities of people. As part of the study, a research team led by Prof. Dr. Hendrik Streeck and Prof. Dr. Gunther Hartmann from the University of Bonn and members of the Cluster of Excellence ImmunoSensation2 carried out a large study to precisely determine the infection fatality rate for the first time among other findings. The results of the study have been pre-published and are now presented to scientists and the public. Publication in a peer-reviewed journal is to follow.

"The results can be used to further improve models on the transmission behavior of the virus. Until now, basis for such data has been relatively uncertain," says co-author Prof. Dr. Gunther Hartmann, Director of the Institute for Clinical Chemistry and Clinical Pharmacology at the University Hospital Bonn and speaker of the Cluster of Excellence, ImmunoSensation2. The study also provides important indicators for further research on SARS-CoV-2 such as: the infection risk dependent on age, gender and pre-existing conditions; the increased severity of illness amidst special circumstances of a massive infection incident such as in Gangelt, or on the risk of infection within families.


Publication

Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event Hendrik Streeck, Bianca Schulte, Beate M. Ku¨mmerer, Enrico Richter, Tobias Höller, Christine Fuhrmann, Eva Bartok, Ramona Dolscheid, Moritz Berger, Lukas Wessendorf, Monika Eschbach-Bludau, Angelika Kellings, Astrid Schwaiger, Martin Coenen, Per Hoffmann, Birgit Stoffel-Wagner, Markus M. Nöthen, Anna-Maria Eis-Hu¨binger, MartinExner, Ricarda Maria Schmithausen, Matthias Schmid and Gunther Hartmann, https://www.medrxiv.org/content/10.1101/2020.05.04.20090076v2


Contact for the media

Dr. Andreas Archut

University Communications

University of Bonn

Phone: +49 (0)228 73-7647

E-Mail: kommunikation@uni-bonn.de

Related news

Pandyra Publication Graphical Abstract

News categories: Publication

Genetic mutation affects survival after viral infection

Scientists discovered that haploinsufficiency in the Pax5 gene affects antiviral responses. The study was led by Prof. Dr. Aleksandra Pandyra from the Institute of Clinical Chemistry and Clinical Pharmacology at the University Hospital Bonn in collaboration with Prof. Dr. Arndt Borkhardt, Clinic Director at the Pediatric Oncology at the University Hospital Düsseldorf. The findings were published in the latest edition of EMBO Molecular Medicine.
View entry
AG Kürthen Multiple Sclerosis Bonn

News categories: Publication

Potential target for MS therapy discovered

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system caused by the immune system. B cells, which are a type of white blood cell, play a role in the development of MS and are thus a target for therapies. Researchers at the University Hospital Bonn (UKB), the University of Bonn and the FAU Erlangen-Nuremberg identified the membrane protein MLC1 as a potential target antigen in MS. The results of the work have now been published in the renowned journal “Neurology Neuroimmunology & Neuroinflammation”.
View entry
NLRP3 Alzheimers McManus

News categories: Publication

Reducing Neuroinflammation Could Help Fight Alzheimer’s

Alzheimer’s disease is the most common cause of dementia. A promising approach for its treatment is the prevention of inflammatory processes in the brain. An international team of scientists around Dr. Róisín McManus, Prof. Eicke Latz and Prof. Michael Heneka now provide new evidence supporting this approach and potentially contributing to the development of more effective therapies. The results have now been published in the journal “Immunity”.
View entry

Back to the news overview